Draft Genome Sequence of Streptomyces rapamycinicus Strain NRRL 5491, the Producer of the Immunosuppressant Rapamycin
Open Access
- 29 August 2013
- journal article
- Published by American Society for Microbiology in Microbiology Resource Announcements
- Vol. 1 (4)
Abstract
Streptomyces rapamycinicus strain NRRL 5491 produces the important drug rapamycin. It has a large genome of 12.7 Mb, of which over 3 Mb consists of 48 secondary metabolite biosynthesis clusters.Keywords
This publication has 14 references indexed in Scilit:
- mTOR signaling for biological control and cancerJournal of Cellular Physiology, 2013
- mTOR is a key modulator of ageing and age-related diseaseNature, 2013
- mTOR Signaling in Growth Control and DiseaseCell, 2012
- The mTOR Signalling Pathway in Human CancerInternational Journal of Molecular Sciences, 2012
- Fighting neurodegeneration with rapamycin: mechanistic insightsNature Reviews Neuroscience, 2011
- Five new members of the Streptomyces violaceusniger 16S rRNA gene clade: Streptomyces castelarensis sp. nov., comb. nov., Streptomyces himastatinicus sp. nov., Streptomyces mordarskii sp. nov., Streptomyces rapamycinicus sp. nov. and Streptomyces ruanii sp. nov.International Journal of Systematic and Evolutionary Microbiology, 2008
- Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activitiesProceedings of the National Academy of Sciences, 2008
- Drug-Eluting StentsCardiology in Review, 2007
- SIROLIMUS (RAPAMYCIN)-BASED THERAPY IN HUMAN RENAL TRANSPLANTATIONTransplantation, 1999
- Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle.The Journal of Antibiotics, 1975